Cargando…

Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic

COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to pot...

Descripción completa

Detalles Bibliográficos
Autores principales: Shields, Stephanie, Dunlop, Allan, Seenan, John Paul, Macdonald, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231430/
https://www.ncbi.nlm.nih.gov/pubmed/34249322
http://dx.doi.org/10.1136/flgastro-2020-101563
_version_ 1783713423163392000
author Shields, Stephanie
Dunlop, Allan
Seenan, John Paul
Macdonald, Jonathan
author_facet Shields, Stephanie
Dunlop, Allan
Seenan, John Paul
Macdonald, Jonathan
author_sort Shields, Stephanie
collection PubMed
description COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to potential risk of viral transmission and non-emergency endoscopies and surgeries cancelled, the secondary impact on chronic illnesses such as inflammatory bowel disease (IBD) is becoming apparent. Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a dramatic drop in TDM testing since the pandemic onset. April 2020 saw a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing when compared with February 2020 data, a reduction coinciding with the widespread cancellation of outpatient and elective activity. It is feared that disruption to normal patterns of care and disease monitoring of biologic patients could increase the risk of disease flare and adverse clinical outcomes. Urgent changes in clinical practice have been instigated to mitigate the effects of the pandemic on routine clinical care. Further transformations are needed to maintain safe, effective, patient-centred IBD care in the future.
format Online
Article
Text
id pubmed-8231430
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82314302021-07-09 Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic Shields, Stephanie Dunlop, Allan Seenan, John Paul Macdonald, Jonathan Frontline Gastroenterol Colorectal COVID-19 has dominated life in 2020 with, at the time of writing, over 4.9M global cases and >320 000 deaths. The impact has been most intensely felt in acute and critical care environments. However, with most UK elective work postponed, laboratory testing of faecal calprotectin halted due to potential risk of viral transmission and non-emergency endoscopies and surgeries cancelled, the secondary impact on chronic illnesses such as inflammatory bowel disease (IBD) is becoming apparent. Data from the Scottish Biologic Therapeutic Drug Monitoring (TDM) service shows a dramatic drop in TDM testing since the pandemic onset. April 2020 saw a 75.6% reduction in adalimumab testing and a 36.2% reduction in infliximab testing when compared with February 2020 data, a reduction coinciding with the widespread cancellation of outpatient and elective activity. It is feared that disruption to normal patterns of care and disease monitoring of biologic patients could increase the risk of disease flare and adverse clinical outcomes. Urgent changes in clinical practice have been instigated to mitigate the effects of the pandemic on routine clinical care. Further transformations are needed to maintain safe, effective, patient-centred IBD care in the future. BMJ Publishing Group 2020-09-30 /pmc/articles/PMC8231430/ /pubmed/34249322 http://dx.doi.org/10.1136/flgastro-2020-101563 Text en © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. https://bmj.com/coronavirus/usageThis article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
spellingShingle Colorectal
Shields, Stephanie
Dunlop, Allan
Seenan, John Paul
Macdonald, Jonathan
Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title_full Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title_fullStr Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title_full_unstemmed Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title_short Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic
title_sort disease monitoring of biologic treatment in ibd: early impact and future implications of covid-19 pandemic
topic Colorectal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231430/
https://www.ncbi.nlm.nih.gov/pubmed/34249322
http://dx.doi.org/10.1136/flgastro-2020-101563
work_keys_str_mv AT shieldsstephanie diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic
AT dunlopallan diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic
AT seenanjohnpaul diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic
AT macdonaldjonathan diseasemonitoringofbiologictreatmentinibdearlyimpactandfutureimplicationsofcovid19pandemic